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Purpose: Bone metastasis from stomach cancer occurs only rarely and it is known to have a very poor prognosis. This study examined 
the clinical characteristics and prognosis of patients who were diagnosed with stomach cancer and bone metastasis.
Materials and Methods: The subjects were 19 patients who were diagnosed with stomach cancer at Hanyang University Medical Center 
from June 1992 to August 2010 and they also had bone metastasis. The survival rate according to many clinicopathologic factors was 
retrospectively analyzed.
Results: 11 patients out of 18 patients (61%) who received an operation were in stage IV and the most common bone metastasis loca-
tion was the spine. Bone scintigraphy was mostly used for diagnosing bone metastasis and PET-CT and magnetic resonance imaging   
were used singly or together. The serum alkaline phosphatase at the time of diagnosis had increased in 12 cases and there were clinical 
symptoms (bone pain) in 16 cases. Treatment was given to 14 cases and it was mostly radiotherapy. There were 2 cases of discovering 
bone metastasis at the time of diagnosing stomach cancer. The interval after operation to the time of diagnosing bone metastasis for the 
18 cases that received a stomach cancer operation was on average 14.9±17.3 months and the period until death after the diagnosis 
of bone metastasis was on average 3.8±2.6 months. As a result of univariate survival rate analysis, the group that was treated for bone 
metastasis had a significantly better survival period when the bone metastasis was singular rather than multiple, as compared to the 
non-treatment group, yet both factors were not independent prognosis factors on multivariate survival analysis. 
Conclusions: An examination to confirm the status of bone metastasis when conducting a radio-tracer test after the initial diagnosis 
and also after an operation is needed for stomach cancer patients, and bone scintigraphy is the most helpfully modality. Making the 
diagnosis at the early stage and suitable treatments are expected to enhance the survival rate and improve the quality of life even for the 
patients with bone metastasis. 
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Introduction
The proportion of gastric cancer patients among the annually 
registered cancer patients in Korea is as high as approximately 20%.(1) 
It is very important to assess the presence or absence of metastasis 
to establish the treatment plans for gastric cancer, which occurs at 
such a high rate, and to predict the prognosis. Gastric cancer gen-
erally metastasizes to the peritoneal membrane, liver, lymph nodes, 
etc., and it may metastasize to the spleen, adrenalin, ovary, lung, 
brain and skin. 
Bone metastasis generally occurs in patients with prostate can-
cer, breast cancer and lung cancer, and bone metastasis in gastric 
cancer patients has been shown to be very rare.(2-4) Bone metas-
tasis is usually associated with disseminated vascular coagulation, 
hemolytic anemia and other hematological complications, and the 
prognosis is very poor.(5) The diverse incidence and prognosis of 
bone metastasis from gastric cancer have been reported in numer-
ous studies, but this has not been sufficiently established in Korea. 
Therefore, we conducted this study to examine the clinical charac-
teristics of the patients diagnosed with gastric cancer by gastroscopy 
as well as histological tests, and these patients had bone metastasis 
detected simultaneously or later, and we also wanted to assess their 
prognosis.
Copyright © 2011 by The Korean Gastric Cancer Association www.jgc-online.orgStomach Cancer with Bone Metastasis
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Materials and Methods
1. The subjects
The study was conducted on 19 patients who were diagnosed as 
having gastric caner with bone metastasis by histological tests from 
June 1992 to August 2010 in the Department of Surgery, Hanyang 
University Hospital. 
2. Methods
Bone scintigraphy (Fig. 1), PET-CT (Fig. 2), and magnetic 
resonance imaging (MRI) were used as the methods of diagnos-
ing bone metastasis. All the patients with bone metastasis were 
classified according to Borrmann’s morphology as assessed by the 
gastroscopic findings, the location of the gastric cancer and the 
histological types, and their correlations with bone metastasis were 
analyzed. In addition, the preferential site of bone metastasis, and 
the association with lung metastasis and brain metastasis were ex-
amined. In addition, by measuring the serum alkaline phosphatase 
(ALP) value, the changes of the ALP value in patients with bone 
metastasis was examined (Table 1), and the difference of the mor-
tality rate according to with or without treatments for bone me-
tastasis was analyzed, as well as the treatment methods SPSS 13.0 
(statistical Package for Social Science version 13.0, SPSS Inc., Chi-
cago, IL, USA) was used for the data analysis, the survival rate was 
obtained by the Kaplan-Meier method and the significance of the 
Table 1. Clinicopathological characteristics
Factor Subfactor No.
Sex Male/Female 13/6
Age (yr*) Mean 55.4±9.7
Median 57.0
Range 40~74
Type of surgery Subtotal gatrectomy   7
Total gastrectomy 10
Gastrojejunostomy  1
No surgery   1
TNM stage Ib   1
II  3
IIIa  2
IIIb  1
IV 12
Histology WEL  1
MOD  4
POR  8
SIG  5
MUC  1
Borrmann type 1   0
2 4
31 2
4 3
Site of primary tumor Lower 1/3   7
Middle 1/3   8
Upper 1/3   2
Whole stomach   2
No. of metastatic Mean 17.2±14.5
  lymph node Median 17.0
Range 0~43
No. of dissected Mean 34.4±15.6
  lymph node Median 35.0
Range 0~60
No. = number; yr = year; TNM = tumor node metastasis; WEL = well 
differentiated adeno  carcinoma; MOD = moderated differentiated 
adenocarcinoma; POR = poorly diff  erentiated adenocarcinoma; SIG = 
signet ring cell carcinoma; MUC = mucinous carcinoma.
Fig. 1. Bone scintigraphy shows increased uptake in multifocal area.
Fig. 2. PET-CT shows increased uptake in the vertebra, paravertebral 
muscle .Ahn JB, et al.
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difference of the survival rate was validated by the log-rank test. 
Cox’s proportional hazard model was used  for multivariate analysis 
of the survival rate and P-values less than 0.05 were considered to 
be statistically significant. 
Results
1. Clinicopathological characteristics of the gastric 
cancer
Eighteen among the 19 subjects received surgery. Total gastrec-
tomy was performed on 10 patients, subtotal gastrectomy was per-
formed on 7 patients and gastrojejunostomy was performed on 1 
patient. In regard to the disease stage of gastric cancer according to 
the AJCC 6th edition, Ib was 1 case (5%), II was 3 cases (15%), IIIa 
was 2 cases (10%), IIIb was 1 case (5%), and IV was 12 cases (63%). 
Stage IV was the most prevalent. The patients were divided into 
early gastric cancer and advanced gastric cancer according to the 
macroscopic morphology observed on gastroscopy, and advanced 
gastric cancer was defined as cases from Borrmann’s type 1 to type 
4. In the 19 patients, there were 4 cases of Borrmann’s type 2 (21%), 
12 case of  Borrmann’s type 3 (63%) and 3 cases of Borrmann’s 
type 4 (16%). Concerning the histological types, there was 1 case 
of highly differentiated cancer, 4 cases of moderately differentiated 
cancer, 8 cases of poorly differentiated cancer, 5 cases of signet 
ring cell carcinoma and 1 case of mucinous adenocarcinoma. The 
undifferentiated type (14/19, 73%) was more abundant than the 
differentiated types (5/19, 27%) (Table 1).
2. Clinicopathological characteristics of bone metastasis
The area of bone metastasis was in the order of the vertebrae 
(17 cases, 89%), the costa (12 cases, 63%), the lower extremities (2 
cases, 10 %), the scapula (2 cases, 10%) and the upper extremities 
(1 case, 5%). In regard to the diagnosis of bone metastasis lesions, 
there were 9 patients diagnosed by bone scintigraphy alone, 3 pa-
tients were diagnosed by using only positron emission tomography-
computed tomography and 1 patient was diagnosed by magnetic 
resonance imaging alone. In the remaining 6 cases, together with 
bone scintigraphy, positron emission tomography-computed to-
mography and magnetic resonance imaging were used simultane-
ously. In other words, bone scintigraphy was used most frequently 
for the diagnosis. There were 5 patients (26%) with a solitary lesion 
at the time of diagnosis and there were 14 patients (74%) with 
multiple lesions at the time of diagnosis. Concerning the serum 
ALP level at the time of the diagnosis of bone metastasis, it was 
higher than the normal values (30~110 U/L) in 12 cases (66%), 
the median value was 190 U/L and the average value was 484.4±
785.6 U/L. Backache, bone pain and other symptoms pertinent to 
bone metastasis were noted in 16 cases (88%). Nine patients (47%), 
were diagnosed bone metastasis only without distant metastasis, 
there was 1 case of bone metastasis together with brain metastasis, 
one case was associated with metastasis in the skin and periaortic 
lymph node metastasis, there were 2 cases associated with liver 
metastasis and periaortic lymph node metastasis, there was 1 case 
associated with liver metastasis and peritoneal dissemination, there 
was 1 case associated with peritoneal dissemination only, there 
were 2 cases associated with lung metastasis and one case was as-
sociated with Virchow’s node metastasis. Excluding the 5 cases 
whose general condition deteriorated due to the progression of gas-
tric cancer and so they could not be treated, 14 cases (73%) were 
treated. Twelve cases were treated with radiation therapy alone, 
1 case was treated with systemic injection of chemotherapeutics 
and 1 case was treated with the combination treatment of systemic 
injection of chemotherapeutic agents and radiation therapy. All 13 
patients treated with radiation therapy presented with bone pain 
caused by bone metastasis. After irradiation with 3,000~3,500 rad, 
9 patients (69.2%) showed the amelioration of symptoms. One pa-
tient who was administered systemic chemotherapeutic agents did 
not have symptoms associated with bone metastasis. In 2 cases, 
bone metastasis was detected at the time of the diagnosis of gastric 
cancer. In 18 cases, the interval from surgery to the diagnosis of 
bone metastasis was on average 14.9±17.3 months (median value: 
9 months, range: 0 ~73 months). The period from the diagnosis of 
bone metastasis to death was on average 3.8±2.6 months (median 
value: 3 months, range: 1~9 months (Table 2).
3. The survival period of the gastric cancer patients with 
bone metastasis
In regard to the average survival period according to gender, 
that for the males was 3.4±0.7 months, that for the females was 
4.7±1.1 months and there was no significant difference (P=0.401). 
Based on the age of 60 years, the survival rate of the 5 patients 
older than 60 years and the 14 patients older than 60 years was 4.6
±0.8 months and 3.5±0.7 months, respectively, and a significant 
difference was not shown (P=0.620) (Table 1). For the univari-
ate analysis of the survival rate according to the number of bone 
metastasis lesions, the average survival period was 6.2±1.2 months 
and 2.9±0.5 months for patients with solitary and multiple lesions, 
respectively, and the survival period of the patients with a solitary Stomach Cancer with Bone Metastasis
41
Table 2. Clinicopathological characteristics of bone metastasis
Factor Subfactor No.
Site of recurrence Bone 9
Bone+branin 1
Bone+local 1
Bone+skin+lymph node 1
Bone+liver+lymph node 2
Bone+peritoneum 1
Bone+lung 2
Bone+Virchow’s node 1
Bone+liver+peritoneum 1
Site of bone metastasis Numerous 8
Vertebra 5
Vertebra+rib 2
Vertebra+rib+scapula 1
Vertebra+femur 1
Rib+knee 1
Scapula+humerus 1
Diagnostic modality Bone scan 9
PET-CT 3
Bone scan+PET-CT 3
MRI 1
Bone scan+MRI 3
Bone pain Present 16
Absent 3
Alkaline phosphatase Mean 482.4±785.6
  serum level (U/L) Median 190.0
Range 34~3,300
Treatment of bone  Radiotherapy 12
  metastasis Chemotherapy 1
Chemo-radiotherapy 1
None 5
Time to recurrence Mean 14.9±17.3
  aft  er operation (mo) Median 9.0
Range 0~73
Time to death Mean 3.8±2.6
  aft  er recurrence (mo) Median 3.0
Range 0~9
No. = number; MRI = magnetic resonance imaging; mo = month.
lesion was significantly longer than that of the patients with mul-
ticentric lesions (P=0.031). Nonetheless, the results of multivariate 
analysis showed that the number of metastatic lesions was not an 
independent prognostic factor. The survival period of the 16 cases 
of Borrmann’s types 2 and 3 was compared with that of the 3 cases 
of Borrmann’s type 4. The survival period was 3.9±0.7 months 
and 3.0±1.2 months, respectively, and a statistically significant dif-
ference was not shown (P=0.502). On the analysis of the survival 
period according to the disease stage, the survival period of the 
three groups (4 cases of stages 1 and 2, 3 cases of stage 3 and 12 
cases of stage 4) after the diagnosis of bone metastasis was 2.5±
0.9 months, 3.0±1.0 months and 4.4±0.8 months, respectively, 
and a statistically significant difference was not shown (P=0.224). 
When the survival period according to the histological types was 
compared, that for the differentiated type was 2.8±0.8 months, that 
for the undifferentiated type was 4.1±0.7 months and a statisti-
cally significant difference was not shown (P=0.228). The survival 
period for the 9 cases with metastatic lesions in the bone only was 
compared with that of the 10 cases with metastasis in other organs 
in addition to the bone was compared, and it was 4.6±0.8 months 
and 3.3±0.9 months, respectively, and the difference between the 
two groups was not significant (P=0.375). The survival period of 
the 14 patients treated for bone metastasis was compared with the 5 
patients who were not  treated and it was 4.4±0.7 months and 2.0
±0.4 months, respectively. The survival period of the treated group 
Table 3. Univariate survival analysis of gastric cancer patient with 
bone metastasis
Factor Subfactor No.
Duration 
of survival 
(mean±SD)
P
Sex Male 13 3.4±0.7 0.401
Female 6 4.7±1.1
Age (yr) <60 14 3.5±0.7 0.620
≥60 5 4.6±0.8
Histology Diff  erentiated 5 2.8±0.8 0.228
Undiff  erendiated 14 4.1±0.7
Borrmann type 1~3 16 3.9±0.7 0.502
4 3 3.0±1.2
Stage Ib+II 4 2.5±0.9 0.224
IIIa+IIIb 3 3.0±1.0
IV 12 4.4±0.8
Site of recurrence Bone only 9 4.6±0.8 0.375
Bone and other site 10 3.3±0.9
Treatment of Performed 14 4.4±0.7 0.019
 bone metastasis Not performed 5 2.0±0.4
Number of Single 5 6.2±1.2 0.031
 bone metastasis Multiple 14 2.9±0.5
No. = number; SD = standard deviation; yr = year.Ahn JB, et al.
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was significantly higher (P=0.019). Nonetheless, on the multivariate 
analysis of the survival period, it was not an independent prognostic 
factor (Table 3, 4).
Discussion
Bone metastasis frequently occurs in patients with breast cancer, 
lung cancer, renal cancer, prostate cancer, bladder cancer and other 
primary cancers. In comparison, it has been shown that bone me-
tastasis that originates from malignant tumors of the gastrointestinal 
tract is rare.(2-4) In 1983, Yoshikawa and Kitaoka(6) reported that 
the incidence of bone metastasis is 1~20%. In 1987, Nishidoi and 
Koga(7) have reported that in 246 gastric cancer patients, bone me-
tastasis was associated in 33 patients (13.4%). In our study, among 
the 2,150 patients diagnosed with gastric cancer from June 1992 
to August 2010, bone metastasis was associated in 19 patients for 
a frequency of 0.9%. In other words, depending on the research 
institutions and investigators, the incidence of bone metastasis var-
ies greatly. Seto et al.(8) have reported that bone scintigraphy was 
performed on 60 patients, and bone metastasis was suspected in 
25% of these patients. Bone metastasis may occur more frequently 
in cases with primary cancer in the body of stomach, poorly dif-
ferentiated adenocarcinoma and in cases with abundant lymph 
node metastasis in the vicinity. In our study, like as shown in the 
study reported by Seto et al., the undifferentiated histological types 
(14/19, 73%) were more abundant than the differentiated types 
(5/19, 27%). However, the survival period of the two groups was 
not significantly different. Thus, the survival period was not dif-
ferent according to the histological types. In 1995, Choi et al.(9) 
performed bone scintigraphy on 234 gastric cancer patients, and 
based on the presence or absence of hot uptake lesions, the fre-
quency and pattern of bone metastasis were inferred and reported. 
According to this, there were 106 patients who showed  hot uptake 
lesions, the estimated incidence of bone metastasis was 45.3% and 
an elevated serum ALP value was associated with bone metastasis. 
In our study, similarly, among the 19 patients, the serum ALP value 
was elevated in 12 patients at the time of diagnosis. Similarly, in 
2006, Kusumoto et al.(10) reported on the clinical characteristics 
of 9 patients with bone metastasis from gastric cancer, and it was 
observed that the serum ALP level was elevated in all 9 patient, and 
the serum ALP value was an important factor for making the diag-
nosis of bone metastasis. Therefore, it is thought that in patients di-
agnosed with gastric cancer, if the ALP value is atypically elevated, 
then evaluation of bone metastasis is required. 
In our study, bone scintigraphy was applied most frequently for 
the diagnosis of bone metastasis (15/19, 78%). In addition, posi-
tron emission tomography-computed tomography and MRI were 
used alone or in combination. On account of the use of a gamma 
camera and the development of test agents such as Tc-99m MDP, 
the sensitivity of bone scintigraphy is particularly high, and thus it 
is known to be the most useful screening test. Bone scintigraphy 
could detect the change of abnormal blood flow within the bone 
that developed metastasis, and so it could detect bone metastasis at 
the time approximately 3 months earlier than that with using plain 
X-rays.(11,12) Nevertheless, hot uptake lesions may be detected 
in Paget’s disease and other metabolic bone diseases, degenerative 
arthritis, fractures, infectious bone diseases and other benign bone 
diseases or primary bone tumors, and so it has limitations of low 
specificity. In our study, among the 19 patients, there were only 5 
patients with a solitary lesion. Several studies have examined the 
rate of detecting bone metastasis with a solitary lesion as detected 
by bone scintigraphy, and only approximately 50~55% of the cases 
were diagnosed as having bone metastasis.(13-16) In other words, 
bone scintigraphy has shortcomings that it is difficult to diagnose 
bone metastasis from malignant tumors in the cases with a hot up-
take lesion. Therefore, it is considered that for cases with a solitary 
hot uptake lesion detected by bone scintigraphy, together with ac-
curate history taking for fracture and other past medical problems, 
the rate of a false diagnosis of bone metastasis from gastric cancer 
could be decreased by making an accurate differential diagnosis 
from infectious bone diseases, metabolic bone diseases and other 
benign diseases. In our study, for the cases that a solitary lesion 
Table 4.  Survival rate of gastric cancer patient aft  er bone metastasis (multivariate analysis)
Factor Signifi  cance B 95% confi  dence interval
Treatment of bone metastasis Yes
 No 0.143 0.386 0.108~1.381
Number of bone metastasis Single
 Multiple 0.359 0.359 0.096~1.347Stomach Cancer with Bone Metastasis
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was detected by bone scintigraphy, efforts were made to increase 
the accuracy of the diagnosis by additionally performing positron 
emission tomography-computed tomography or magnetic reso-
nance imaging. The accuracy of the diagnosis may be increased 
more by performing additional bone marrow tapping or bone mar-
row histological tests in parallel. Choi et al.(9) have reported that 
the area where bone metastasis was frequently diagnosed by bone 
scintigraphy was in the order of the vertebrae (66%), the costa (59%), 
the pelvic bone (43%), the femur (30%) and the scapula and clavicle 
(17%). In our study, among the 19 patients, metastasis in the ver-
tebrae was detected in 17 cases (89%), and so similar results were 
obtained. Other metastases associated with bone metastasis were 
also examined, and particularly, 3 of the 19 patients (15%) were as-
sociated with liver cancer. In general, for gastric cancer and includ-
ing early gastric cancer, the most frequently metastasized area by 
hematogenous metastasis is the liver.(10) In our gastric cancer pa-
tients, the rate of liver metastasis was lower than the general rate of 
liver metastasis. This could be explained by the difference of me-
tastasis routes. In the cases with well differentiated tumors, metas-
tasis is developed through the portal vein. On the other hand, in the 
cases with poorly differentiated cancer, bone metastasis primarily 
occurs through the vertebral vein system.(8,17) Several studies have 
reported that the vertebrae are the site where bone metastasis oc-
curs most frequently, which supports that the vertebral vein system 
is the major route of bone metastasis.(9,12,18) Kusumoto et al.(10) 
have reported that in patients with gastric cancer, bone metastasis is 
more prevalent in the young age groups, but in our study, age was 
not found to be correlated with bone metastasis. In bone metasta-
sis from gastric cancer, the cancer cells diffusely proliferate in the 
bone marrow and this can cause disseminated carcinomatosis; they 
also proliferate rapidly and thus induce bone destruction as well as 
hematological complications. Yet the developmental mechanism of 
bone destruction has not yet been elucidated. More studies on this 
are required.(10) 
Yoshikawa and Kitaoka(6) and Nishidoi and Koga(7) have re-
ported that bone metastasis from gastric cancer is associated with 
Borrmann’s types 3 and 4, which arereferred to as scirrhous carci-
noma. In our study, similarly, Borrmann’s types 3 and type 4 were 
found in 17 cases of the entire 19 cases (89%), and these results are 
similar to those of the above studies. In regard to the association 
with the disease stage of primary gastric cancer, the 11 patients 
who underwent surgery (61%) were stage IV. In other words, in the 
Borrmann type 3 and 4 patients, bone metastasis occurs frequently 
in the cases with primary cancer of a high disease stage. Nonethe-
less, the macroscopic type and disease stage were not significantly 
correlated with the survival period after the diagnosis of bone 
metastasis. Yet the number of cases in each disease stage was too 
small, and a  comparative analysis of the survival period of each 
disease stage could not be performed. Analysis of a larger num-
ber of cases is required for a clearer interpretation of the results of 
the analysis of our study(that the survival period according to the 
disease stages was not different. Among the 19 patients diagnosed 
with bone metastasis, 5 cases could not be treated because of the 
deterioration of their general condition due to the progression of 
gastric cancer, and the remaining 14 patients were treated. On the 
univariate analysis of the survival period of the treatment group 
and the non-treatment group, the survival period of the treatment 
group was 4.4±0.7 months and it was significantly longer than the 
2.0±0.4 survival period of the untreated group. The most common 
clinical symptoms and complications of bone metastasis are bone 
pain, pathologic fracture and spinal cord compression. In our study, 
similarly, in the 19 subject patients, the majority or 16 patients (84%) 
were positive for bone pain. Clinically, the cause of the worst suf-
fering of patients with bone metastasis is bone pain. Therefore, 
pain management for patients with bone pain is very important. 
In regard to radiation therapy for such bone pain, Murai et al.(19) 
have reported that 68 patients with bone metastasis were classi-
fied according to the type of primary tumors, and radiation therapy 
was effective in 73% of the lung cancer patients, 100% of the breast 
cancer patients and 75% of the gastric cancer patients. In addition, 
Y oshikawa and Kitaoka(20) have reported that in 23 gastric cancer 
patients associated with bone metastasis, radiation therapy was ef-
fective for the amelioration of bone pain, yet chemotherapy was 
not effective for this. McQuay et al.(21) have reported that in regard 
to the effectiveness of radiation therapy for the amelioration of 
bone pain, 1 month after the treatment, the bone pain was resolved 
completely in 1/4 of the patients, and at least 50% pain amelioration 
could be obtained in 1/3 of the patients. The survival period of was 
recently improved by treatment with MTX+5FU, S1+paclitaxel, 
S1+cisplatin and other chemotherapy,(22,23) and in addition it was 
effective on the amelioration of pain.(24) Bisphosphonate(25) has 
recently been used for the treatment of clinical symptoms caused 
by bone metastasis and the complications. It suppressed the pro-
duction of proliferative factors by bones through the suppression of 
the reabsorption of bone, and thus it suppressed the proliferation of 
cancer cells.(26,27) Therefore, in patients with bone metastasis, it 
reduces pain and it also suppresses or delays complications caused 
by bone metastasis. Nonetheless, large scale studies on bone me-Ahn JB, et al.
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tastasis patients have not been conducted, and studies are needed 
on the indications for the use of Bisphosphonate and to prove its 
treatment effectiveness. Chung et al.(28) reported on 4 patients 
with bone metastasis caused by gastric cancer, and all 4 patients 
died within 4 months after the diagnosis of bone metastasis. In our 
study, similarly, the period from the diagnosis of bone metastasis 
to death was on average 3.8±2.6 months, and it was found that the 
prognosis was very poor. 
In conclusion, the prognosis of bone metastasis caused by gastric 
cancer is very poor and the prognosis of patients may be worsened 
due to a delayed diagnosis. Hence, tests to assess for bone metas-
tasis are required for gastric cancer patients at the time of the initial 
diagnosis and the postsurgical follow-up observation, and bone 
scintigraphy with its high sensitivity appears to be most useful. In 
such a manner, it is anticipated that the survival period as well as 
the quality of life may be improved with making a rapid diagnosis 
and by administering radiation therapy and other appropriate treat-
ments. Studies with a large number of larger subjects are required 
to assess the effect ofimproving  the survival period according to 
different treatment methods.
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